Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma
Open Access
- 20 December 2001
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 115 (4), 793-800
- https://doi.org/10.1046/j.1365-2141.2001.03147.x
Abstract
The prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the assessment of post-treatment residual masses in patients with Hodgkin's disease (HD) or non-Hodgkin's lymphomas (NHL) was evaluated. We prospectively studied 58 patients with HD (n = 43) or NHL (n = 15) who had post-therapeutic complete remission with residual masses (CRu) indicated by computerized tomography. Analysis of 62 residual locations by FDG-PET was performed separately for HD and NHL. Patients with a PET-positive residual mass [standardized uptake value (SUV) > 3] had a recurrence rate of 62·5% (5/8 patients), whereas patients with PET-negative residual mass (SUV ≤ 3·0) showed a recurrence rate of 4% (2/50 patients, P = 0·004). A positive FDG-PET study correlated with a significantly poorer progression-free survival (P < 0·00001). No recurrence occurred in any of the 39 HD patients with a negative PET scan (negative predictive value, 100%). Four out of four NHL patients with a positive PET study relapsed (positive predictive value, 100%). In conclusion, FDG-PET is a suitable non-invasive method with a high degree of accuracy in the prediction of early recurrence in lymphoma patients with CRu.This publication has 33 references indexed in Scilit:
- FDG Positron Emission Tomography in the Diagnosis of Peripheral Pulmonary Focal LesionsThe Thoracic and Cardiovascular Surgeon, 2000
- Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?European Journal of Cancer, 2000
- Residual Mass in Aggressive Lymphoma - Does Size, Measured by Computed Tomography, Influence Clinical Outcome?Acta Oncologica, 2000
- Diagnostic Accuracy of F-18 FDG-PET in the Assessment of Posttherapeutic Recurrence of Head and Neck CancerClinical Positron Imaging, 1999
- Gallium Scan in the Evaluation of Post Chemotherapy Mediastinal Residual Masses of Aggressive Non-Hodgkin's LymphomaLeukemia & Lymphoma, 1999
- 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphomaNuclear Medicine Communications, 1997
- Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucoseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Restaging laparotomy in the management of the non-Hodgkin lymphomasMedical and Pediatric Oncology, 1982
- On the Origin of Cancer CellsScience, 1956